+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Lung Cancer Drugs Market by Therapeutic Class, Cancer Type, Molecule Type, Route of Administration, Product Category, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Lung Cancer Drugs Market by Therapeutic Class, Cancer Type, Molecule Type, Route of Administration, Product Category, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Lung Cancer Drugs Market by Therapeutic Class, Cancer Type, Molecule Type, Route of Administration, Product Category, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896738
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Lung Cancer Drugs Market is projected to reach USD 32.61 Billion in 2026. It is expected to continue growing at a CAGR of 9.20%, reaching USD 55.43 Billion by 2032.

Lung cancer drugs are central to oncology innovation because lung cancer remains the world’s leading cause of cancer death. IARC’s GLOBOCAN 2022 estimates about 2.5 million new lung cancer cases and 1.8 million deaths worldwide, underscoring persistent unmet need despite earlier diagnosis, tobacco-control progress, and expanding screening programs.

The lung cancer drugs landscape is increasingly shaped by precision oncology, immunotherapy, antibody-drug conjugates, targeted small molecules, and biomarker-led treatment sequencing. Non-small cell lung cancer accounts for most diagnoses and dominates clinical development, while small cell lung cancer remains an area of high therapeutic need. Progress depends on proven overall survival benefit, reliable companion diagnostics, equitable access, and real-world evidence that supports value-based oncology decisions.

Transformative Shifts in the Lung Cancer Drug Landscape

The lung cancer treatment landscape has shifted from broad chemotherapy toward molecularly defined care. EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK, HER2, KRAS G12C, and PD-L1 testing now influence treatment selection, helping clinicians match patients with targeted therapies or immune checkpoint inhibitors when supported by approved indications and clinical guidelines.

Competition is moving toward next-generation resistance management, earlier-line therapy, perioperative immunotherapy, and combination regimens. Drug developers are also prioritizing brain metastasis activity, improved safety, and oral convenience. Payers and health systems are demanding stronger comparative evidence, while regulators continue to emphasize confirmatory trials, post-marketing safety, and validated diagnostics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is influencing lung cancer drugs across discovery, trial design, diagnosis, and commercial strategy. AI-enabled image analysis supports nodule detection and radiology workflow, while computational biology helps identify drug targets, resistance mechanisms, and patient subgroups that may benefit from specific regimens.

The cumulative impact is operational as well as scientific. Sponsors use machine learning to improve site selection, protocol feasibility, safety-signal detection, and real-world evidence generation. Adoption must remain governed by clinical validation, data quality, bias monitoring, privacy safeguards, and transparent regulatory documentation, particularly when AI outputs affect patient selection or treatment decisions.

Key Regional Insights

Asia-Pacific is a major demand center for lung cancer drugs because of high disease burden, large patient populations, and expanding oncology infrastructure in China, Japan, South Korea, India, Australia, and ASEAN markets. China has accelerated oncology review mechanisms and strong domestic innovation in EGFR inhibitors, PD-1/PD-L1 agents, and antibody-drug conjugate programs, while Japan and South Korea remain leaders in precision medicine adoption, genomic testing, and clinical development. Australia supports guideline-based care and high-quality cancer registries, while India and Southeast Asian markets show rising need for affordable targeted therapy, immunotherapy, and molecular diagnostics.

North America continues to set the pace for premium oncology launches, with the United States supported by FDA oncology pathways, broad biomarker testing, guideline influence, and extensive clinical trial activity. Canada benefits from advanced cancer centers and public reimbursement review, although provincial coverage variability can affect access timing. Europe shows strong evidence-based adoption through EMA review, health technology assessment, and national reimbursement negotiation across the European Union, United Kingdom, Germany, France, Italy, and Spain, with treatment decisions closely tied to demonstrated survival benefit, quality-of-life outcomes, and cost-effectiveness.

Latin America, the Middle East, and Africa present growth opportunities but face uneven access to molecular testing, specialist care, and high-cost immuno-oncology drugs. Brazil and Mexico anchor Latin American demand through a mix of public systems and private oncology networks. Middle Eastern markets, especially GCC countries, are investing in cancer centers, national screening strategies, and specialist capacity. African markets require stronger early diagnosis, pathology infrastructure, supply-chain resilience, oncology workforce development, and affordability programs to improve access to evidence-based lung cancer treatment.

Key Group Insights

ASEAN markets are expanding lung cancer treatment capacity through public-private hospital investment, broader pathology networks, and gradual adoption of targeted therapy and immunotherapy. Access remains mixed across Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines, making pricing strategy, diagnostics partnerships, clinician education, and local evidence essential for improving uptake of biomarker-driven lung cancer drugs.

The GCC is increasingly important for premium oncology therapies as Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman invest in cancer centers, national health transformation programs, and specialist oncology services. The European Union provides a sophisticated but fragmented reimbursement environment, where centralized regulatory review is only the first step before country-level health technology assessment determines adoption speed, patient eligibility, and pricing conditions.

BRICS countries combine high patient volume with diverse regulatory and affordability conditions, especially across China, India, Brazil, Russia, and South Africa. These markets require localized access models, broader diagnostic capacity, and evidence aligned with public-sector decision-making. G7 markets remain central to launch sequencing, clinical evidence generation, and pricing benchmarks because of advanced oncology infrastructure and mature reimbursement systems. NATO countries overlap significantly with high-income oncology systems, but procurement resilience, medicine supply security, and cross-border clinical research capacity increasingly influence strategic planning.

Key Country Insights

The United States is a leading innovation and commercialization hub for lung cancer drugs, supported by FDA oncology pathways, Medicare and commercial coverage, advanced molecular diagnostics, and high clinical trial density. Canada offers strong specialty cancer care and provincial oncology programs, but reimbursement timing and formulary decisions vary by province. Mexico and Brazil are key Latin American markets where public-sector access, private oncology networks, specialist availability, and diagnostic infrastructure determine uptake of targeted therapy and immunotherapy.

In Europe, the United Kingdom, Germany, France, Italy, and Spain use structured health technology assessment and national reimbursement processes to evaluate overall survival, progression-free survival, quality of life, and budget impact. Germany often provides early post-approval access under AMNOG assessment, while the United Kingdom relies on NICE value assessment to guide reimbursement. France, Italy, and Spain emphasize therapeutic added value and negotiated access, while Russia maintains meaningful oncology demand but faces regulatory, geopolitical, reimbursement, and supply-chain complexity.

China is a high-growth lung cancer drugs market with strong domestic oncology development and expanding access to targeted and immunotherapy agents through national reimbursement negotiations. India has high unmet need and growing private oncology care, but affordability, diagnostic availability, and geographic disparities remain critical. Japan, South Korea, and Australia combine advanced diagnostics, guideline-driven care, organized reimbursement pathways, and high-quality clinical research, making them important countries for evidence generation, biomarker adoption, and premium therapy access.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-led strategies that integrate drug development with validated companion diagnostics, pathology workflow support, and clinician education. Organizations that reduce time from biopsy to treatment decision can strengthen clinical outcomes, treatment confidence, and adoption of precision lung cancer drugs.

Developers should invest in resistance-targeting assets, rational combinations, antibody-drug conjugates, and earlier-stage disease indications where survival gains can be clinically meaningful. Commercial teams should align launch plans with payer evidence requirements, including overall survival, progression-free survival, quality-of-life data, safety, comparative effectiveness, and real-world outcomes. Access programs, tiered pricing, patient support, and local partnerships are critical in emerging markets where testing capacity and affordability remain barriers.

Research Methodology

This executive summary is based on triangulation of public, verifiable sources, including IARC GLOBOCAN 2022 cancer statistics, World Health Organization cancer burden references, FDA and EMA oncology approval information, major clinical guideline frameworks, peer-reviewed oncology literature, and publicly available health technology assessment practices.

The analysis emphasizes validated disease burden, regulatory trends, therapy-class evolution, regional access conditions, and observable adoption drivers. Insights were synthesized using market-structure assessment, treatment pathway mapping, regulatory review, and comparative regional analysis. No unsupported market-size figures, market-share claims, or unverified forecasts are used.

Conclusion

The lung cancer drugs landscape is advancing rapidly as precision oncology, immunotherapy, and biomarker-enabled treatment reshape standards of care. Sustained progress will depend on therapies that demonstrate clinically meaningful survival benefit, manage resistance, improve tolerability, and address patients earlier in the disease pathway.

The next phase of competition will reward organizations that combine scientific differentiation with diagnostic access, payer-ready evidence, AI-enabled development efficiency, and region-specific commercialization models. Stakeholders that align innovation with affordability, supply reliability, and real-world outcomes will be best positioned to improve lung cancer care globally.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Lung Cancer Drugs Market, by Therapeutic Class
7.1. Chemotherapy
7.2. Combination Therapy
7.3. Immunotherapy
7.3.1. Ctla-4 Inhibitors
7.3.2. Pd-1 Inhibitors
7.3.3. Pd-L1 Inhibitors
7.4. Targeted Therapy
7.4.1. Alk Inhibitors
7.4.2. EgfR Inhibitors
7.4.3. Ros1 Inhibitors
8. Lung Cancer Drugs Market, by Cancer Type
8.1. Non Small Cell Lung Cancer
8.2. Small Cell Lung Cancer
9. Lung Cancer Drugs Market, by Molecule Type
9.1. Monoclonal Antibodies
9.2. Small Molecule Drugs
10. Lung Cancer Drugs Market, by Route Of Administration
10.1. Oral
10.2. Parenteral
11. Lung Cancer Drugs Market, by Product Category
11.1. Branded
11.2. Generic
12. Lung Cancer Drugs Market, by End User
12.1. Homecare Settings
12.2. Hospitals
12.3. Specialty Clinics
13. Lung Cancer Drugs Market, by Distribution Channel
13.1. Hospital Pharmacy
13.2. Online Pharmacy
13.3. Retail Pharmacy
14. Asia-Pacific Lung Cancer Drugs Market
15. Europe Lung Cancer Drugs Market
16. North America Lung Cancer Drugs Market
17. Latin America Lung Cancer Drugs Market
18. Africa Lung Cancer Drugs Market
19. Middle East Lung Cancer Drugs Market
20. NATO Lung Cancer Drugs Market
21. G7 Lung Cancer Drugs Market
22. BRICS Lung Cancer Drugs Market
23. European Union Lung Cancer Drugs Market
24. ASEAN Lung Cancer Drugs Market
25. GCC Lung Cancer Drugs Market
26. China Lung Cancer Drugs Market
27. United States Lung Cancer Drugs Market
28. Japan Lung Cancer Drugs Market
29. India Lung Cancer Drugs Market
30. Germany Lung Cancer Drugs Market
31. United Kingdom Lung Cancer Drugs Market
32. Australia Lung Cancer Drugs Market
33. France Lung Cancer Drugs Market
34. South Korea Lung Cancer Drugs Market
35. Italy Lung Cancer Drugs Market
36. Canada Lung Cancer Drugs Market
37. Russia Lung Cancer Drugs Market
38. Brazil Lung Cancer Drugs Market
39. Mexico Lung Cancer Drugs Market
40. Spain Lung Cancer Drugs Market
41. Competitive Landscape
41.1. Market Concentration Analysis, 2025
41.1.1. Concentration Ratio (CR)
41.1.2. Herfindahl Hirschman Index (HHI)
41.2. Recent Developments & Impact Analysis, 2025
41.3. Product Portfolio Analysis, 2025
41.4. Benchmarking Analysis, 2025
42. Company Profiles
42.1. AbbVie Inc.
42.2. Amgen Inc.
42.3. Astellas Pharma Inc.
42.4. AstraZeneca PLC
42.5. Bayer AG
42.6. BeiGene, Ltd.
42.7. Blueprint Medicines Corporation
42.8. Boehringer Ingelheim International GmbH
42.9. Bristol-Myers Squibb Company
42.10. Daiichi Sankyo Company, Limited
42.11. Eisai Co., Ltd.
42.12. Eli Lilly and Company
42.13. Exelixis, Inc.
42.14. F. Hoffmann-La Roche Ltd
42.15. Gilead Sciences, Inc.
42.16. GlaxoSmithKline plc
42.17. Incyte Corporation
42.18. Innovent Biologics, Inc.
42.19. Johnson & Johnson
42.20. Kyowa Kirin Co., Ltd.
42.21. Lupin Limited
42.22. Menarini Group
42.23. Merck & Co., Inc.
42.24. Novartis AG
42.25. Ono Pharmaceutical Co., Ltd.
42.26. Pfizer Inc.
42.27. Roche Holding AG
42.28. Sanofi S.A.
42.29. Sun Pharmaceutical Industries Limited
42.30. Takeda Pharmaceutical Company Limited
42.31. Teva Pharmaceutical Industries Ltd.
42.32. Viatris Inc.
42.33. Zai Lab Limited
List of Figures
FIGURE 1. GLOBAL LUNG CANCER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL LUNG CANCER DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL LUNG CANCER DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL LUNG CANCER DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 27. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. NATO LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. NATO LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. G7 LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. G7 LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. GCC LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. GCC LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. CHINA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. JAPAN LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. INDIA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. GERMANY LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. FRANCE LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. ITALY LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. CANADA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. RUSSIA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. BRAZIL LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. MEXICO LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. SPAIN LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL LUNG CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ALK INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ALK INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ALK INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL EGFR INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL EGFR INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL EGFR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ROS1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ROS1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ROS1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NON SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NON SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NON SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 99. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 100. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 101. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 102. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 103. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 104. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 105. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 129. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 130. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 131. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 132. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 133. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 134. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 135. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. NATO LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 148. NATO LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 149. NATO LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 150. NATO LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 151. NATO LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 152. NATO LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 153. NATO LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. NATO LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 155. NATO LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. NATO LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 157. G7 LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 158. G7 LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 159. G7 LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 160. G7 LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 161. G7 LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 162. G7 LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 163. G7 LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. G7 LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 165. G7 LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. G7 LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. BRICS LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 168. BRICS LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 169. BRICS LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 170. BRICS LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 171. BRICS LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 172. BRICS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 173. BRICS LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 174. BRICS LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 175. BRICS LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. BRICS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 187. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 188. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 189. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 190. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 191. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 192. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 193. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 194. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 195. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 196. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 197. GCC LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 198. GCC LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 199. GCC LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 200. GCC LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 201. GCC LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 202. GCC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 203. GCC LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 204. GCC LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 205. GCC LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. GCC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. CHINA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 208. CHINA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 209. CHINA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 210. CHINA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 211. CHINA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 212. CHINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 213. CHINA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 214. CHINA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 215. CHINA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 216. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 227. JAPAN LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 228. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 229. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 230. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 231. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 232. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 233. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 234. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 235. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 237. INDIA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 238. INDIA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 239. INDIA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 240. INDIA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 241. INDIA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 242. INDIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 243. INDIA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 244. INDIA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 245. INDIA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 246. INDIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 247. GERMANY LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 248. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 249. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 250. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 251. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 252. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 253. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 254. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 255. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 256. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 264. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 265. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 266. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 267. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 268. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 269. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 270. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 271. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 272. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 273. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 274. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 275. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 276. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 277. FRANCE LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 278. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 279. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 280. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 281. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 282. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 283. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 284. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 285. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 286. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 287. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 288. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 289. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 290. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 291. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 292. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 293. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 294. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 295. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 296. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 297. ITALY LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 298. ITALY LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 299. ITALY LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 300. ITALY LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 301. ITALY LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 302. ITALY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 303. ITALY LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 304. ITALY LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 305. ITALY LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 306. ITALY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 307. CANADA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 308. CANADA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 309. CANADA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 310. CANADA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 311. CANADA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 312. CANADA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 313. CANADA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 314. CANADA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 315. CANADA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 316. CANADA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 317. RUSSIA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 318. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 319. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 320. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 321. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 322. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 323. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 324. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 325. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 326. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 327. BRAZIL LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 328. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 329. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 330. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 331. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 332. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 333. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 334. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 335. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 336. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 337. MEXICO LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 338. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 339. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 340. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 341. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 342. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 343. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 344. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 345. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 346. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 347. SPAIN LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 348. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 349. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 350. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 351. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 352. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 353. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 354. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
TABLE 355. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 356. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Lung Cancer Drugs market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Innovent Biologics, Inc.
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • Lupin Limited
  • Menarini Group
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zai Lab Limited

Table Information

Report AttributeDetails
No. of Pages185
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 32.61 Billion
Forecasted Market Value ( USD ) by 2032 $ 55.43 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned34

Related Topics

Related Reports

Lung Cancer Treatment Market - Global Strategic Business Report - Product Image

Lung Cancer Treatment Market - Global Strategic Business Report

  • Report
  • 373 Pages
  • Global
From
Extensive Stage Small Cell Lung Cancer Market - Global Forecast 2026-2032 - Product Image

Extensive Stage Small Cell Lung Cancer Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Non-small Cell Lung Cancer Therapeutics Market by Treatment Type, Line of Therapy, Biomarker Expression, End User, Distribution Channel - Global Forecast 2026-2032 - Product Image

Non-small Cell Lung Cancer Therapeutics Market by Treatment Type, Line of Therapy, Biomarker Expression, End User, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report - Product Image

Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Non-Small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 981 Pages
  • Global
From

About the Lung Cancer Drugs Market

The Lung Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat lung cancer. These drugs are used to treat both non-small cell and small cell lung cancer, the two most common types of lung cancer. The drugs are designed to target the cancer cells and stop them from growing and spreading. Common treatments include chemotherapy, targeted therapy, immunotherapy, and radiation therapy. The Lung Cancer Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies such as Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Roche are all major players in the market. These companies are constantly researching and developing new drugs to treat lung cancer, as well as improving existing treatments. In addition, there are many smaller companies that specialize in the development of new drugs for the treatment of lung cancer. These companies often collaborate with larger pharmaceutical companies to bring their drugs to market. Examples of these companies include ImmunoGen, Inc., Oncolytics Biotech, and ImmunoCellular Therapeutics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.